MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity

Anna Skucha, Jessica Ebner, Johannes Schmöllerl, Mareike Roth, Thomas Eder, Adrián César-Razquin, Alexey Stukalov, Sarah Vittori, Matthias Muhar, Bin Lu, Martin Aichinger, Julian Jude, André C. Müller, Balázs Gyorffy, Christopher R. Vakoc, Peter Valent, Keiryn L. Bennett, Johannes Zuber, Giulio Superti-Furga, Florian Grebien

Research output: Contribution to journalArticle

16 Citations (Scopus)


MLL-fusions represent a large group of leukemia drivers, whose diversity originates from the vast molecular heterogeneity of C-terminal fusion partners of MLL. While studies of selected MLL-fusions have revealed critical molecular pathways, unifying mechanisms across all MLL-fusions remain poorly understood. We present the first comprehensive survey of protein-protein interactions of seven distantly related MLL-fusion proteins. Functional investigation of 128 conserved MLL-fusion-interactors identifies a specific role for the lysine methyltransferase SETD2 in MLL-leukemia. SETD2 loss causes growth arrest and differentiation of AML cells, and leads to increased DNA damage. In addition to its role in H3K36 tri-methylation, SETD2 is required to maintain high H3K79 di-methylation and MLL-AF9-binding to critical target genes, such as Hoxa9. SETD2 loss synergizes with pharmacologic inhibition of the H3K79 methyltransferase DOT1L to induce DNA damage, growth arrest, differentiation, and apoptosis. These results uncover a dependency for SETD2 during MLL-leukemogenesis, revealing a novel actionable vulnerability in this disease.

Original languageEnglish
Article number1983
JournalNature communications
Issue number1
Publication statusPublished - Dec 1 2018

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Fingerprint Dive into the research topics of 'MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity'. Together they form a unique fingerprint.

  • Cite this

    Skucha, A., Ebner, J., Schmöllerl, J., Roth, M., Eder, T., César-Razquin, A., Stukalov, A., Vittori, S., Muhar, M., Lu, B., Aichinger, M., Jude, J., Müller, A. C., Gyorffy, B., Vakoc, C. R., Valent, P., Bennett, K. L., Zuber, J., Superti-Furga, G., & Grebien, F. (2018). MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nature communications, 9(1), [1983].